Utility of Measured Microdosimetric Single Event Spectra in Interpreting Quality of Radiation Fields Used in BNCT

2001 ◽  
pp. 647-651
Author(s):  
Chandrasekhar Kota ◽  
Jay Burmeister ◽  
Richard Maughan
Keyword(s):  
Single Event ◽  
Radiation Fields

Single-event multilevel surgery for crouching cerebral palsy children: Correlations with quality of life and functional mobility

2018 ◽  
Vol 2 (4) ◽  
pp. 148 ◽  
Author(s):  
John Amen ◽  
TamerA El-Sobky ◽  
Mohamed ElGebeily ◽  
DaliaM. E. El.Mikkawy ◽  
AhmedH Yousry
Keyword(s):  
Quality Of Life ◽  
Cerebral Palsy ◽  
Functional Mobility ◽  
Single Event ◽  
Multilevel Surgery

scholarly journals Local and Systemic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation

2014 ◽  
Vol 2014 ◽  
pp. 1-14 ◽  
Author(s):  
Elvio G. Russi ◽  
Judith E. Raber-Durlacher ◽  
Stephen T. Sonis
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Inflammatory Responses ◽  
Tissue Injury ◽  
Traditional Approach ◽  
Symptom Clusters ◽  
Radiation Fields ◽  
Clonogenic Cell

Treatment-related toxicities are common among patients with head and neck cancer, leading to poor clinical outcomes, reduced quality of life, and increased use of healthcare resources. Over the last decade, much has been learned about the pathogenesis of cancer regimen-related toxicities. Historically, toxicities were separated into those associated with tissue injury and those with behavioural or systemic changes. However, it is now clear that tissue-specific damage such as mucositis, dermatitis, or fibrosis is no longer the sole consequence of direct clonogenic cell death, and a relationship between toxicities that results in their presentation as symptom clusters has been documented and attributed to a common underlying pathobiology. In addition, the finding that patients commonly develop toxicities representing tissue injury outside radiation fields and side effects such as fatigue or cognitive dysfunction suggests the generation of systemic as well as local mediators. As a consequence, it might be appropriate to consider toxicity syndromes, rather than the traditional approach, in which each side effect was considered as an autonomous entity. In this paper, we propose a biologically based explanation which forms the basis for the diverse constellation of toxicities seen in response to current regimens used to treat cancers of the head and neck.

Quality of life in youngsters with cerebral palsy after single-event multilevel surgery

2013 ◽  
Vol 17 (4) ◽  
pp. 401-406 ◽  
Author(s):  
E. Himpens ◽  
I. Franki ◽  
D. Geerts ◽  
R. Tack ◽  
R. Van der Looven ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cerebral Palsy ◽  
Single Event ◽  
Multilevel Surgery

Accelerated Hyperfractionation of Radiotherapy for Rapidly Growing Inoperable Breast Cancer Unresponsive to Chemotherapy

1992 ◽  
Vol 78 (5) ◽  
pp. 326-329 ◽  
Author(s):  
Dimitrios Giannakakis ◽  
Michael Koukourakis ◽  
Anastasia Sotiropoulou ◽  
Haralambos Zambatis ◽  
John Scarlatos
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Breast Carcinoma ◽  
Acute Toxicity ◽  
Late Complications ◽  
Low Grade ◽  
Radiation Fields ◽  
Multidrug Chemotherapy

Eleven patients with rapidly growing inoperable breast carcinoma were treated with a thrice-a-day fractionation of 1.2 Gy per fraction (5-h intervals, 15 fractions per week). Nine of them had been considered as non-responders to previous aggressive multidrug chemotherapy. A split of 2 weeks was inserted after 54 Gy, and radiation fields were then restricted to the clinical positive area up to a total tumor dose of 90 Gy. Nine of 11 patients completed their treatment, and 7 of them were considered as complete responders. Acute toxicity was surprisingly low (grade I-II). Four patients surviving 12-18 months after radiotherapy did not relapse and did not present any late complications. A favorably improved quality of life was obtained for all 9 patients.

scholarly journals What is the functional mobility and quality of life in patients with cerebral palsy following single-event multilevel surgery?

2020 ◽  
Vol 14 (2) ◽  
pp. 139-144 ◽  
Author(s):  
Tomos Aled Edwards ◽  
Robin John Prescott ◽  
Julie Stebbins ◽  
James Wright ◽  
Tim Theologis
Keyword(s):  
Quality Of Life ◽  
Cerebral Palsy ◽  
Functional Mobility ◽  
Single Event ◽  
School Work ◽  
Multilevel Surgery ◽  
Long Term Follow Up

Purpose To report functional mobility in patients with diplegic cerebral palsy (CP) at long-term follow-up after single-event multilevel surgery (SEMLS). The secondary aim was to assess the relationship between functional mobility and quality of life (QoL) in patients previously treated with SEMLS. Methods A total of 61 patients with diplegic CP, mean age at surgery 11 years, eight months (sd 2 years, 5 months), were included. A mean of eight years (sd 3 years, 10 months) after SEMLS, patients were contacted and asked to complete the Functional Mobility Scale (FMS) questionnaire over the telephone and given a weblink to complete an online version of the CP QOL Teen. FMS was recorded for all patients and CP QOL Teen for 23 patients (38%). Results Of patients graded Gross Motor Function Classification System (GMFCS) I and II preoperatively, at long-term follow-up the proportion walking independently at home, school/work and in the community was 71% (20/28), 57% (16/28) and 57% (16/28), respectively. Of patients graded GMFCS III preoperatively, at long-term follow-up 82% (27/33) and 76% (25/33) were walking either independently or with an assistive device at home and school/work, respectively, while over community distances 61% (20/33) required a wheelchair. The only significant association between QoL and functional mobility was better ‘feelings about function’ in patients with better home FMS scores (r = 0.55; 95% confidence interval 0.15 to 0.79; p = 0.01). Conclusion The majority of children maintained their preoperative level of functional mobility at long-term follow-up after SEMLS. Level of Evidence IV

Next Generation Well Design and Integrity Digital Tools: Boosting Drilling Systems Automation (DSA)

2019 ◽  
Author(s):  
B. Brechan ◽  
S. Dale ◽  
S. Sangesland
Keyword(s):  
Current Practice ◽  
Reporting System ◽  
Digital Tools ◽  
Single Event ◽  
Next Generation ◽  
Event Type ◽  
Software Support ◽  
Planning Team ◽  
Well Design

Abstract The first of the next generation applications for well planning and operational support is under development. All aspects of construction, integrity, intervention and final plugging of wells are supported and fully automated into digital programs and procedures. Expanding the scope of software support entails a change from current practice of simulating all activity upfront to keep the model active and updated to supply all integrity data through production and final plugging of the well. The software is built to carry executable experience. These “digital experiences” range from the single event type often noted during operations, to complex sets of instructions in governing documentation. Experiences act as rules for how the software select methods outlined in activity plans and how these plans are executed by the equipment on drill floor. Any activity plan, e.g. drilling, completion, intervention or plug and abandonment (P&A), will be established using the entire company portfolio of experience regardless of the capacity and experience of the planning team. Engineers working with the next generation software will focus on ensuring the quality of the produced digital procedures. The software will handle administrative routines, such as invoicing and logistics, which will free up capacity for engineers. The user threshold of the next generation software will be low for any person familiar with the daily operational reporting system.

Improvement of cancer care by linking community cancer center oncologists to disease site-specific experts.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6641-6641
Author(s):  
Patricia H. Hardenbergh ◽  
Calloway B May ◽  
Kimberly Anne Lyons-Mitchell
Keyword(s):  
Radiation Oncology ◽  
Cancer Care ◽  
Daily Practice ◽  
Practice Change ◽  
Cancer Center ◽  
Site Specific ◽  
Radiation Fields ◽  
Community Physician ◽  
Disease Site

6641 Background: To improve the quality of cancer care across US by connecting community cancer center oncologists with highly specialized, disease site-specific oncologists through the use of online technology. Methods: Chartrounds.com was developed which allows community oncologists to interact online with disease site-specific oncologists and their peers on a scheduled basis in order to present and review treatment management and specific cases. Disease sites include breast, head and neck, gastrointestinal, gynecologic, prostate, central nervous systems, pediatric, lymphoma, lung cancer and palliative care. At the conclusion of each session, participants are asked to complete a questionnaire which requests feedback on the quality and relevance of the session and the manner in which it might result in practice changes. Results: To date, 825 community radiation oncology physician members from 50 states and 19 countries have enrolled online. In the initial 25-month period (12/2010-1/2013), 35 disease site-specific specialists have lead 256 chart rounds one-hour sessions with an average attendance ratio of 15 community physician members to 1 disease site-specific specialist. On a 5 point scale with 5 representing the greatest impact possible, of 1,756 responses the mean score to feedback questions is as follows: session quality: 4.6, time used effectively: 4.6, discussions relevant to daily practice: 4.6, session is likely to result in a change in practice: 4.0.Members reported that they would make the following changes in their practice: change in clinical management of the radiation patient: 40%, change in the selection of patients for radiation: 10%, change in radiation fields: 15%, change in radiation prescription dose: 10%. Conclusions: The Chartrounds.com program appears to be making an impact on the quality of radiation oncology practices resulting in changes in management and treatment of patients in community cancer centers. Future directions of this project are aimed at continuing to develop the site for medical oncologists and multidisciplinary tumor conferences. This work is funded by the Improving Cancer Care Grant of the ASCO Conquer Cancer Foundation supported by Susan G. Komen for the Cure.

Evaluation of the effectiveness of a new medical device containing verbascoside, polyvinylpyrrolidone, and hyaluronic acid in prevention and treatment of mucositis in patients with cancer.

2018 ◽  
Vol 36 (34_suppl) ◽  
pp. 206-206
Author(s):  
Olga Nigro
Keyword(s):  
Complete Remission ◽  
Cancer Patients ◽  
Oral Mucositis ◽  
Mucosal Injury ◽  
Oral Solution ◽  
Patients With Cancer ◽  
Radiation Fields ◽  
Oral Environment ◽  
Prevention And Treatment

206 Background: Mucosal injury is the consequence of biologic events coupled with the influence of the oral environment and microbiome. Oral mucositis is one of the most common toxicities of chemoradiation therapies. Incidence and severity varies by chemoradiation regimens, radiation fıelds, and tumor site. The influence of mucositis on quality of life is greater among patients than the medical literature would suggest. Lack of experience in evaluating treatment toxicities is a daily problem in cancer patients. The aim of this study was to assess the efficacy of verbascoside’s (mucosyte) oral solution on mucositis in cancer patients. Methods: Fourty-five patients with different grade mucositis treated with mucosyte (ranging from 1-2 to 6-7 rinses/day, according to the guidelines) were evaluated from October 2017 to June 2018. Patients were monitored every week until complete remission. Results: Of 45 patients enrolled, 5 had G1 oral mucositis at baseline, 21 had G2, 13 had G3 and 3 had G4. Three patients had G0 oral mucositis at baseline. Median age was 66.8 years. Six patients were treated with carboplatin/paclitaxel, and six with cisplatin/pemetrexed for non-small cell lung cancer; nine patients were treated with paclitaxel, six with adriamycin/cyclophosphamide, and two with eribulin for breast cancer; four patients were treated with FOLFOX for intestinal adenocarcinoma; three patients were treated with nab-paclitaxel/gemcitabine for pancreatic cancer; five patients were treated with cisplatin/cetuximab, and four with cisplatin/cetuximab plus radiotherapy for squamous-cell head and neck cancer. All patients reached complete remission in a median time of 14.9 days (10-24 days). Conclusions: Mucosyte treatment was able to rapidly shorten G3/4 oral mucositis to G1/2, and to never happen mucositis in G0 at baseline. Thus, we suggest that mucosyte can be effective both in prevention and treatment of mucositis.

Sign in / Sign up

Export Citation Format

Share Document